Supreme Court Refuses to Hear Medicare Drug Lawsuits
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Supreme Court declined to hear the lawsuits challenging the Medicare drug price negotiation program.
- AstraZeneca and five other drugmakers—Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk—were the plaintiffs in the challenges.
- The justices gave no explanation for their denial of review.
- Lower courts had already ruled against the drugmakers, and the Supreme Court typically declines cases when lower courts agree.
Why it matters: The decision lets the Medicare negotiation program move forward, preserving the administration's effort to lower prescription costs for seniors while denying the six drugmakers a chance to block the rule.
